Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

ISC 2021 Using data of the AHA COVID-19 CVD Registry, risk of ischemic stroke was 0.75% in patients hospitalized with COVID-19, which is lower than previously reported.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

The ACC has published a statement with key clinical risk considerations that offers guidance on the incorporation of CV risk into vaccine allocation prioritizing decisions.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Four leading CV organizations, the WHF, ACC, AHA and ESC, have published a joint statement as a call for action to reduce the impact of air pollution on people’s health.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

Patients with HF admitted to hospital for COVID-19 had increased risk for in-hospital mortality and needed more often ICU care and intubation and mechanical ventilation compared to patients without HF.

This position paper discusses the cause and consequences of endothelial injury and dysfunction in COVID-19.

A study of 305 hospitalized COVID-19 patients showed that approximately two-third of patients with evidence of myocardial injuries had echocardiographic abnormalities. In these patients, risk of in-hospital mortality was increased.

AHA 2020 Anthony Fauci gives a presentation on COVID-19: Public health and scientific challenges.

This viewpoint article in JAMA reviews the latest findings on the risk of heart failure, particularly HFpEF, in those who developed acute COVID-19 and those who have recovered from the illness.